Literature DB >> 7318306

Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease.

L A Bauer, R A Blouin.   

Abstract

Theophylline total body clearance was calculated in 59 adult patients requiring intravenous aminophylline therapy. Group 1 consisted of 36 chronic obstructive pulmonary disease patients who were cigarette smokers without other conditions known to alter theophylline kinetics (age range: 22 to 79 years). Group 2 consisted of 23 chronic obstructive pulmonary disease patients who were cigarette smokers with a similar degree of congestive heart failure, but free of other characteristics or diseases that affect theophylline disposition (age range: 41 to 81 years). When individual theophylline total body clearance values were plotted against age in each group, poor correlation coefficients were found, indicating that age is not a good predictor of total body clearance of theophylline (group 1: r = 0.101; group 2: r = 0.276). Each group was also broken into 'younger' and 'older' patients. No significant differences in theophylline total body clearance values were found between the younger and older patients for either group I or 2, suggesting that a theophylline dosage reduction is not necessary in cigarette smoking patients over an arbitrary age limit.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7318306     DOI: 10.2165/00003088-198106060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  18 in total

1.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

2.  Effects of age and cigarette smoking on propranolol disposition.

Authors:  R E Vestal; A J Wood; R A Branch; D G Shand; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

3.  Computer-assisted digoxin therapy.

Authors:  C C Peck; L B Sheiner; C M Martin; D T Combs; K L Melmon
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

4.  Pharmacokinetics of theophylline in ten elderly patients.

Authors:  F Nielsen-Kudsk; I Magnussen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-03

5.  Intravenous theophylline therapy: nomogram guidelines.

Authors:  W J Jusko; J R Koup; J W Vance; J J Schentag; P Kuritzky
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

6.  Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination.

Authors:  A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

7.  Oral aminophylline therapy. Increased dosage requirements in children.

Authors:  D E Zaske; K W Miller; E L Strem; S Austrian; P B Johnson
Journal:  JAMA       Date:  1977-04-04       Impact factor: 56.272

8.  Theophylline clearance: effect of marked obesity.

Authors:  R A Blouin; J F Elgert; L A Bauer
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

9.  Theophylline kinetics in relation to age: the importance of smoking.

Authors:  B Cusack; J G Kelly; J Lavan; J Noel; K O'Malley
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

10.  Theophylline disposition in obesity.

Authors:  P Gal; W J Jusko; A M Yurchak; B A Franklin
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

View more
  3 in total

1.  The effect of age on theophylline clearance in normal subjects.

Authors:  W C Randolph; J J Seaman; B Dickson; K E Peace; W O Frank; M D Young
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  Effects of time of dosing and age on intravenous aminophylline pharmacokinetics.

Authors:  A Rodgers; K W Woodhouse; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

Review 3.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.